Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate the efficacy and safety of anakinra in inpatient management of acute gout and pseudogout. METHODS: Hospitalized patients with acute gout (n = 77) or pseudogout (n = 11) or both (n = 3) were analyzed for response to anakinra and adverse effects. RESULTS: Half of all patients had comorbidities limiting the treatment choice. Anakinra was well tolerated, and 92% of gout flares and 79% of pseudogout flares responded to treatment. CONCLUSION: Anakinra is an effective and safe treatment for acute gout and pseudogout in hospitalized patients, particularly in those with comorbidities.
No takes yet. Share an insight, caveat, or question.
Desmarais et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: